Kabarriti Gabriel, Elsayed Ali, Moustafa Giannis A, Hodgson Nickisa
Department of Ophthalmology, State University of New York (SUNY) Downstate, Brooklyn, NY, United States.
Department of Ophthalmology, Kings County New York City Health and Hospitals Corporation (NYC HHC), Brooklyn, NY, United States.
Front Ophthalmol (Lausanne). 2025 May 22;5:1576929. doi: 10.3389/fopht.2025.1576929. eCollection 2025.
The purpose of this study is to characterize orbital inflammatory disease (OID) in a primarily Black patient population, examining their demographics, presentations, workup, treatment, and outcome.
A retrospective study was performed from January 2005 to June 2022 at two academic institutions in Brooklyn, NY. Patients included met criteria for one of the following OID conditions: non-specific orbital inflammation; nonbacterial dacryoadenitis; Tolosa-Hunt; orbital myositis; definite, possible, or probable IgG4-related ophthalmic disease; and sclerosing orbital inflammation. Data reviewed included orbital inflammatory labs, imaging, pathology, and treatment. Treatment was considered successful if a patient had complete resolution of symptoms.
Thirty-nine patients met criteria for this study. 35.9% were diagnosed with dacryoadenitis, 28.2% with NSOI, 12.8% with myositis, 5.1% with possible IgG-ROD, 7.7% with probable IgG4-ROD, 7.7% with Tolosa Hunt, and 2.6% with sclerosing OI. 91% were started on steroids; 12.8% required transition to steroid-sparing therapy. 85% had a successful outcome with a resolution of symptoms.
This study characterizes OID in a Black patient population and compares it to prior studies done on OID. Research on underrepresented patient populations is needed to understand differences in disease presentation and improve patient outcomes.
本研究旨在描述以黑人为主的患者群体中的眼眶炎性疾病（OID），研究其人口统计学特征、临床表现、检查、治疗及预后。
2005年1月至2022年6月在纽约布鲁克林的两家学术机构进行了一项回顾性研究。纳入的患者符合以下OID疾病之一的标准：非特异性眼眶炎症；非细菌性泪腺炎；托洛萨-亨特综合征；眼眶肌炎；明确、可能或疑似IgG4相关性眼病；以及硬化性眼眶炎症。回顾的数据包括眼眶炎性实验室检查、影像学检查、病理学检查及治疗情况。如果患者症状完全缓解，则认为治疗成功。
39名患者符合本研究标准。35.9%被诊断为泪腺炎，28.2%为非特异性眼眶炎症，12.8%为肌炎，5.1%为可能的IgG相关性眼眶疾病，7.7%为疑似IgG4相关性眼眶疾病，7.7%为托洛萨-亨特综合征，2.6%为硬化性眼眶炎症。91%开始使用类固醇治疗；12.8%需要转换为类固醇替代疗法。85%的患者症状缓解，治疗成功。
本研究描述了黑人患者群体中的OID，并将其与之前关于OID的研究进行了比较。需要对代表性不足的患者群体进行研究，以了解疾病表现的差异并改善患者预后。
